Mansur KAYATAŞ, Can HÜZMELİ, Ayşe KOÇKARA, Ferhan CANDAN

Neuroleptic malignant syndrome induced acute renal failure: Is mental retardation an additional risk factor?

Nöroleptik malign sendrom, nöroleptik tedavinin nadir; ancak, ciddi bir komplikasyonudur.Sıklıkla klasik antipsikotik ilaçların kullanımına bağlı olarak gelişen ekstrapiramidal semptomlar,hiperpreksi, kan basıncında düzensizlikler, genellikle kaslarda kasılma ve bilinçde değişiklikler ilekarakterize bir hastalıktır. Bu olgu sunumunda mental gerilik olan bir hastada kronik böbrekhastalığı zemininde gelişen ve nöroleptik malign sendromun oluşturduğu akut böbrek yetmezliğinitartışmaktayız.

Nörolep tik malign sendromun oluşturduğu akut böbrek yetmezliği: Mental gerilik ilave bir risk f aktörü mü?

Neuroleptic malignant syndrome is a rare but serious complication of neuroleptic treatment. It is adisorder which is usually characterized by muscle contraction and changes in consciousness,extrapyramidal symptoms, hyperpyrexia and blood pressure irregularities that often depend on theuse of conventional antipsychotic drugs. In this case report, we discuss acute renal failure inducedby neuroleptic malignant syndrome developing on the basis of chronic kidney disease in a patientwith mental retardation.

PDF

___

1. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris) 1960; 118: 145-52.
2. Kaplan HI, Sadock BJ, Grebb JA. Synopsis of Psychiatry, 7th Edition, Baltimore, Williams&Wilkins, 1994; pp: 953.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. 4. Baskı (DSM-IV)Washington DC, American Psychiatric Association 1994; s: 739-42.
4. Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res 1995; 29: 233-44.
5. Ueda M, Hamamoto M, Nagayama H, Okubo S, Amemiya S, Katayama Y. Biochemical alterations during medication withdrawal in Parkinsons disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry 2001; 71: 111-3.
6. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry 1989; 46: 914-8.
7. Berardi D, Amore M, Keck PE Jr, Troia M, Dell'Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998; 44: 748-54.
8. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164: 870-6.
9. Bambrick M, Wilson D. Recurrent neuroleptic malignant syndrome in a man with mild mental handicap. J Intellect Disabil Res 1992; 36: 377-81.
10. Margetic B, Aukst-Margetic B. Neuroleptic malignant syndrome and clozapine withdrawal at the same time? Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 145-7.
11. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77: 185-202.
12. Stübner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundörfer G, Möller HJ, Hippius H, Rüther E. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004; 37(suppl 1): S54- S64.
13. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137-45.
14. Harrigan RA, Brady WJ. Antipsychotics. In: Tintinalli JE, Kelen GD, Stapczynski JS, editors. Emergency medicine.5th ed. New York: McGraw-Hill Companies 2000; pp: 1086-7.
15. Gelder M, Gath D, Mayou R,Cowen P. The neuroleptic malignant syndrome. In: Gelder M, Gath D, Mayou R,Cowen P,editors. Oxford textbook of psychiatry.3rd ed. Oxford University New York 1996; 162-184
16. Patterson JF. Neuroleptic malignant syndrome associated with metoclopramide. South Med J 1988; 81: 674.
17. Doğan N, Kürşad H, Erdem AF, Kızılkaya M. Nöroleptik malign sendromda nadir etyolojik faktörler ve klinik seyir. Atatürk Üniversitesi Tıp Dergisi 2003; 35: 23-6.
18. Nimmagadda SR, Ryan DH, Atkin SL. Neuroleptic malignant syndrome after venlafaxine. Lancet 2000; 355(9200): 289-90.
19. Gupta S, Racaniello AA. Neuroleptic malignant syndrome associated with amoxapine and lithium in an older adult. Ann Clin Psychiatry 2000; 12: 107-9.
20. Ehara H, Maegaki Y, Takeshita K. Neuroleptic malignant syndrome and methylphenidate. Pediatr Neurol 1998; 19: 299-301.
21. Pınar ÇE, Gedizlioğlu M. Neuroleptic malignant-like syndrome due to herbicide intoxication. J Neurological Sciences 2005; 22: 101-3.
22. Martínez HR, Cantú-Martínez L, González HC, Flores Lde L, Villarreal HJ, Onofre-Castillo J. Epilepsy, parkinsonism, and neuroleptic malignant syndrome in a child. J Child Neurol 2006; 21: 1073-5.
23. Naganuma H, Fujii I. Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatr Scand 1994; 90: 424-6.
24. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987; 22: 1004-20.
25. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 1997; 154: 1156-8.
26. Turan M, Kucur R. Nöroleptik malign sendrom ve mental retardasyon: İki olgu sunumu. Klinik Psikiyatri 2001; 4: 134-7.
27. Özdemir FN, Kayataş M, Demirhan B, Güz G, Haberal M :The role of uric asid crystallization in acute renal failure due to rhabdomyolysis developing after neuroleptic malignant syndrome" Acute Renal Failure-Towards 2000, Cairns Convention Centre, Cairns, Australia 1- 3 June 1997 (Abstract Book)
28. Diamond JM, Hayes DD. A case of neuroleptic malignant syndrome in a mentally retarded adolescent. J Adolesc Health Care 1986; 7: 419-22.
29. Boyd RD. Neuroleptic malignant syndrome and mental retardation: review and analysis of 29 cases. Am J Ment Retard 1993; 98: 143-55.
30. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73: 337-47.
31. Korzets Z, Zelter E, Bernheim J. Acute renal failure in the setting of the neuroleptic malignant syndrome. Nephrol Dial Transplant 1996; 11: 885-6.